MedTrace Logo

Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025

NCT03907540 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-05-26

Study results available
· View outcomes & findings →

Summary

Human, absorption, metabolism and excretion study of belumosudil (KD025)

Conditions

Interventions

DRUG

Belumosudil 200 mg tablet

Belumosudil 200 mg tablet, development candidate

DRUG

[14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose

test investigational medicinal product

DRUG

[14C]-KD025 200 mg capsule

test investigational medicinal product

Sponsors & Collaborators

  • Quotient Sciences

    collaborator INDUSTRY

  • Kadmon Corporation, LLC

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-05
Primary Completion
2019-05-20
Completion
2019-05-20

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03907540 on ClinicalTrials.gov